Tourmaline Bio Stock Operating Margin
| TRML Stock | 21.82 0.70 3.11% |
Tourmaline Bio fundamentals help investors to digest information that contributes to Tourmaline Bio's financial success or failures. It also enables traders to predict the movement of Tourmaline Stock. The fundamental analysis module provides a way to measure Tourmaline Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tourmaline Bio stock.
| Last Reported | Projected for Next Year |
Tourmaline | Operating Margin |
Tourmaline Bio Company Operating Margin Analysis
Tourmaline Bio's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Tourmaline Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Tourmaline Bio is extremely important. It helps to project a fair market value of Tourmaline Stock properly, considering its historical fundamentals such as Operating Margin. Since Tourmaline Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tourmaline Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tourmaline Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Tourmaline Bio has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Tourmaline Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tourmaline Bio's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tourmaline Bio could also be used in its relative valuation, which is a method of valuing Tourmaline Bio by comparing valuation metrics of similar companies.Tourmaline Bio is currently under evaluation in operating margin category among its peers.
Tourmaline Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tourmaline Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tourmaline Bio's managers, analysts, and investors.Environmental | Governance | Social |
Tourmaline Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 343.53 M | ||||
| Shares Outstanding | 25.64 M | ||||
| Shares Owned By Insiders | 22.61 % | ||||
| Shares Owned By Institutions | 83.90 % | ||||
| Number Of Shares Shorted | 1.63 M | ||||
| Price To Book | 1.95 X | ||||
| EBITDA | (45.38 M) | ||||
| Net Income | (42.12 M) | ||||
| Total Debt | 415 K | ||||
| Book Value Per Share | 12.52 X | ||||
| Cash Flow From Operations | (28.08 M) | ||||
| Short Ratio | 8.15 X | ||||
| Earnings Per Share | (2.49) X | ||||
| Target Price | 57.29 | ||||
| Number Of Employees | 74 | ||||
| Market Capitalization | 625.17 M | ||||
| Total Asset | 210.29 M | ||||
| Retained Earnings | (62.05 M) | ||||
| Working Capital | 203.87 M | ||||
| Net Asset | 210.29 M |
About Tourmaline Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tourmaline Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tourmaline Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tourmaline Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tourmaline Bio Piotroski F Score and Tourmaline Bio Altman Z Score analysis. For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.49) | Return On Assets (0.24) | Return On Equity (0.32) |
The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.